Exciting news from Aurinia as they showcase LUPKYNIS's potential in Lupus treatment at EULAR 2024!
Aurinia, a leading biopharmaceutical company, made waves with their latest presentation at the European Alliance of Associations for Rheumatology (EULAR) 2024. The spotlight was on LUPKYNIS®, a promising treatment for Lupus, as Aurinia shared its safety and efficacy profile with the audience. The cutting-edge research and developments in Lupus treatment presented by Aurinia at EULAR 2024 are paving the way for innovative solutions in addressing this complex autoimmune disease.
LUPKYNIS®, the flagship product of Aurinia, has been generating buzz in the medical community for its potential in transforming Lupus treatment. With the company's emphasis on safety and efficacy, healthcare professionals and patients alike are eager to see the results of this groundbreaking medication. The oral presentation by Aurinia at EULAR 2024 signifies a significant step forward in the journey towards improved outcomes for Lupus patients.
The recognition and interest surrounding Aurinia's presentation at EULAR 2024 highlight the importance of continuous advancements in Rheumatology. As the Company continues to push the boundaries of medical innovation, the spotlight remains on LUPKYNIS® as a beacon of hope for individuals living with Lupus. Stay tuned for more updates on the revolutionary developments in Lupus treatment!
*Did you know?* - Lupus is a chronic autoimmune disease that can affect various parts of the body, including joints, skin, kidneys, heart, and lungs. - Aurinia's LUPKYNIS® is the first FDA-approved oral therapy for Lupus Nephritis, a severe form of Lupus affecting the kidneys.
(NASDAQ: AUPH) (Aurinia or the Company), today announced an oral presentation at the European Alliance of Associations for Rheumatology (EULAR) 2024 taking ...